Rapamycin Holdings Inc. is seeking to raise $2 million in short-term financing in advance of its planned launch of a Series B fundraising round. The new quest for cash comes as the San Antonio-based drug development company continues advance plans to commercialize its lead drug candidate, eRapa-NP2g, for animal and human use.
